BNP and NT-proBNP-guided Treatment Reduces Mortality in Patients with Chronic Heart Failure
B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) can give useful diagnostic and prognostic information in patients with acute dyspnea and chronic heart failure. Prognosis tends to be better in patients with decreasing BNP levels in response to treatment. A new systematic review provides evidence that medical treatment titrated in accordance with BNP or NT-proBNP levels reduces mortality in chronic heart failure (level 1 [likely reliable] evidence). BNP-guided treatment was compared to usual care guided primarily by clinical symptoms in 1,627 patients with heart failure. Follow-up ranged from 6-18 months. BNP-guided treatment was associated with a significant reduction in all-cause mortality (hazard ratio 0.69, 95% CI 0.55-0.86), with a NNT of 12-40 for 1 year assuming 80% survival in the control group. The benefit was found primarily in patients < 75 years old in 2 trials that stratified patients by age. BNP-guidance was associated with increased use of ACE inhibitors, angiotensin receptor blockers, beta blockers, and aldosterone antagonists but not diuretics (Am Heart J 2009 Sep;158(3):422).
For more information, see the Brain natriuretic peptide (BNP) testing topic in DynaMed.
|